Details of the Drug Combination

General Information of Drug Combination (ID: DCHHHDH)

Drug Combination Name
LY3023414 GDC-0077
Indication
Disease Entry Status REF
DD2 Investigative [1]
Component Drugs LY3023414   DMD9KYF GDC-0077   DMY6WUV
N.A. N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DD2
Zero Interaction Potency (ZIP) Score: 1.958
Bliss Independence Score: 3.547
Loewe Additivity Score: 2.027
LHighest Single Agent (HSA) Score: 1.039

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of LY3023414
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
LY3023414 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Modulator [5]
PI3-kinase alpha (PIK3CA) TTEUNMR PK3CA_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Indication(s) of GDC-0077
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Breast cancer 2C60-2C65 Phase 1 [2]
GDC-0077 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
PI3-kinase gamma (PIK3CG) TTHBTOP PK3CG_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02549989) Study of LY3023414 for the Treatment of Recurrent.
4 ClinicalTrials.gov (NCT04632992) A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC). U.S. National Institutes of Health.
5 Company report (Lilly)